Press Release: Maravai LifeSciences Reports Third Quarter 2026 Financial Results

Dow Jones11-05

Third quarter 2026 total revenue up 10% from prior year

mRNA revenue up 28% year-over-year

SAN DIEGO--(BUSINESS WIRE)--November 04, 2026-- 

Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the third quarter ended September 30, 2026, together with other business updates.

Key Financial Results:

   --  Quarterly revenue of $45.9 million, Net loss of $(24.0) million, and 
      Adjusted EBITDA of $5.8 million; 
 
   --  Full year 2026 revenue guidance range increased to $212.0 million to 
      $216.0 million; Adjusted EBITDA guidance raised to $40.0 million to $42.0 
      million. 

"Our third-quarter results build on the momentum we established in the first half of the year," said Bernd Brust, CEO of Maravai LifeSciences. "TriLink revenue grew 12% year-over-year led by 28% revenue growth for our mRNA products, while Cygnus delivered its sixth consecutive quarter of year-over-year growth, with revenue up 8%."

Brust continued, "Four Discovery mRNA customers transitioned to clinical-stage GMP this quarter, reinforcing our belief that today's Discovery success will create tomorrow's GMP opportunity. Based on our third-quarter performance and our expectations for the fourth quarter, we are raising our full-year revenue and adjusted EBITDA guidance. We remain focused on driving sustained, profitable growth and creating long-term value for our shareholders."

Revenue for the Third Quarter 2026

 
                        Three Months Ended September 30, 
                     -------------------------------------- 
                                          Year-over-Year % 
(Dollars in 000's)      2026      2025          Change 
                     ----------  -------  ----------------- 
TriLink               $  28,350  $25,353              11.8% 
Cygnus                   17,501   16,277               7.5% 
                         ------   ------ 
     Total Revenue    $  45,851  $41,630              10.1% 
                         ======   ====== 
 

Revenue for the Nine Months Ended September 30, 2026

 
                       Nine Months Ended September 30, 
                     ------------------------------------ 
                                         Year-over-Year % 
(Dollars in 000's)     2026      2025         Change 
                     --------  --------  ---------------- 
TriLink              $110,495  $ 85,188             29.7% 
Cygnus                 52,635    50,689              3.8% 
                      -------   ------- 
     Total Revenue   $163,130  $135,877             20.1% 
                      =======   ======= 
 

Third Quarter 2026 Financial Results by Reporting Segment

Revenue for the third quarter was $45.9 million, an increase of 10.1% compared to the prior year period, driven by the following:

   --  TriLink revenue increased 11.8% year-over-year, primarily driven by 
      increased demand for Discovery mRNA and GMP consumables, as well as 
      strength from our CDMO business. 
 
   --  Cygnus revenue increased 7.5% year-over-year, driven by increased 
      demand for Host Cell Protein (HCP) and ELISA kits. 

Net loss and Adjusted EBITDA (non-GAAP) were $(24.0) million and $5.8 million, respectively, for the third quarter of 2026, compared to net loss and Adjusted EBITDA (non-GAAP) of $(45.1) million and $(10.8) million, respectively, for the third quarter of 2025.

Nine Months Ended September 30, 2026 Financial Results by Reporting Segment

Revenue for the nine months ended September 30, 2026 increased 20.1% compared to the prior year period, driven by the following:

   --  TriLink revenue increased 29.7% year-over-year, primarily driven by 
      $14.3 million of high-volume CleanCap orders for commercial phase COVID 
      vaccine programs in Q1 2026. Excluding COVID CleanCap revenue, TriLink 
      base revenue grew 12.9% year-over-year with increased demand for 
      Discovery mRNA and GMP consumables. 
 
   --  Cygnus revenue increased 3.8% year-over-year, driven by demand for HCP 
      and ELISA kits. 

Net loss and Adjusted EBITDA (non-GAAP) were $(52.0) million and $34.8 million, respectively, for the nine months ended September 30, 2026, compared to net loss and Adjusted EBITDA (non-GAAP) of $(167.7) million and $(31.7) million, respectively, for the same period in the prior year.

Updated Financial Guidance for Full Year 2026

Maravai's financial guidance for the full year 2026 is based on expectations for its existing business and does not include the financial impact of potential new acquisitions, if any, or items that have not yet been identified or quantified. This guidance is also subject to a number of risks, uncertainties and other factors, including those identified in "Forward-looking Statements" below.

Revenue for the full year 2026 is now expected to be in the range of $212.0 million to $216.0 million, up from the prior range of $205.0 million to $215.0 million.

Adjusted EBITDA (non-GAAP) is now expected to be in the range of $40.0 million to $42.0 million, up from the prior range of $33.0 million to $35.0 million.

As it relates to forward-looking Adjusted EBITDA, Maravai cannot provide guidance for the most directly comparable GAAP measure or a reconciliation of this non-GAAP financial measure because it is unable to provide a meaningful or accurate calculation or estimation of certain significant reconciling items without unreasonable effort.

Conference Call and Webcast

Maravai's management will host a conference call today at 2:00 p.m. PT / 5:00 p.m. ET to discuss its financial results for the third quarter of 2026 and other business updates. To participate in the conference call by telephone, approximately 10 minutes before the call, dial 1-800-343-4849 or 1-203-518-9894 and reference Maravai LifeSciences, Conference ID: MARAVAI. The call will also be available via live or archived webcast on the "Investors" section of the Maravai web site at https://investors.maravai.com/.

 
                MARAVAI LIFESCIENCES HOLDINGS, INC. 
 
          CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS 
              (in thousands, except per share amounts) 
                             (Unaudited) 
 
                        Three Months Ended      Nine Months Ended 
                           September 30,          September 30, 
                       --------------------  ----------------------- 
                         2026       2025       2026         2025 
                       ---------  ---------  ---------  ------------ 
Revenue                $ 45,851   $ 41,630   $163,130   $ 135,877 
Cost of revenue          29,659     35,975     92,587     114,729 
                        -------    -------    -------    -------- 
Gross profit             16,192      5,655     70,543      21,148 
 
Operating expenses: 
      Selling, 
       general and 
       administrative    30,502     35,456     91,664     113,735 
      Research and 
       development        3,390      3,844     10,981      13,614 
      Goodwill 
       impairment            --         --         --      42,884 
      Restructuring       2,919      7,386      5,764       7,386 
                        -------    -------    -------    -------- 
Total operating 
 expenses                36,811     46,686    108,409     177,619 
                        -------    -------    -------    -------- 
Loss from operations    (20,619)   (41,031)   (37,866)   (156,471) 
Other income 
(expense): 
      Interest 
       expense           (4,027)    (6,844)   (14,585)    (20,437) 
      Interest income       598      2,797      3,630       9,052 
      Loss on 
       extinguishment 
       of debt               --         --     (3,413)         -- 
      Other expense         (27)       (71)      (171)     (4,109) 
                        -------    -------    -------    -------- 
Loss before income 
 taxes                  (24,075)   (45,149)   (52,405)   (171,965) 
Income tax benefit          (75)       (92)      (397)     (4,218) 
                        -------    -------    -------    -------- 
Net loss                (24,000)   (45,057)   (52,008)   (167,747) 
Net loss attributable 
 to non-controlling 
 interests              (10,161)   (19,501)   (22,020)    (72,655) 
                        -------    -------    -------    -------- 
Net loss attributable 
 to Maravai 
 LifeSciences 
 Holdings, Inc.        $(13,839)  $(25,556)  $(29,988)  $ (95,092) 
                        =======    =======    =======    ======== 
 
Net loss per Class A 
 common share 
 attributable to 
 Maravai LifeSciences 
 Holdings, Inc., 
 basic and diluted     $  (0.09)  $  (0.18)  $  (0.20)  $   (0.66) 
Weighted average 
 number of Class A 
 common shares 
 outstanding, basic 
 and diluted            149,067    144,683    147,839     144,119 
 
 
              MARAVAI LIFESCIENCES HOLDINGS, INC. 
 
        RECONCILIATION OF NON-GAAP FINANCIAL INFORMATION 
            (in thousands, except per share amounts) 
                           (Unaudited) 
 
Net Loss to Adjusted EBITDA (non-GAAP) 
                    Three Months Ended      Nine Months Ended 
                       September 30,          September 30, 
                   --------------------  ----------------------- 
                     2026       2025       2026         2025 
                   ---------  ---------  ---------  ------------ 
Net loss           $(24,000)  $(45,057)  $(52,008)  $(167,747) 
Add: 
Amortization          6,466      7,209     19,407      21,439 
Depreciation          5,737      5,975     15,950      17,625 
Interest expense      4,027      6,844     14,585      20,437 
Interest income        (598)    (2,797)    (3,630)     (9,052) 
Income tax 
 benefit                (75)       (92)      (397)     (4,218) 
                    -------    -------    -------    -------- 
      EBITDA         (8,443)   (27,918)    (6,093)   (121,516) 
Acquisition 
 integration 
 costs (1)              312        847        761       2,445 
Stock-based 
 compensation 
 (2)                 10,115      9,056     27,063      26,248 
Merger and 
 acquisition 
 related expenses 
 (3)                     --         --         --       1,270 
Loss on 
extinguishment of 
debt                     --         --      3,413          -- 
Acquisition 
 related tax 
 adjustment (4)          --         --         --       4,082 
Executive 
 leadership 
 transition costs 
 (5)                     --         17         --       2,024 
Goodwill 
 impairment (6)          --         --         --      42,884 
Property and 
 equipment 
 impairment (7)          --          7         --       1,059 
Restructuring 
 costs (8)            2,903      6,932      5,980       6,932 
Other (9)               933        292      3,697       2,846 
                    -------    -------    -------    -------- 
      Adjusted 
       EBITDA 
       (non-GAAP)  $  5,820   $(10,767)  $ 34,821   $ (31,726) 
                    =======    =======    =======    ======== 
 
 
Net Loss attributable to Maravai LifeSciences Holdings, Inc. 
to Adjusted Net Loss (non-GAAP) and Adjusted Fully Diluted 
Loss Per Share (non-GAAP) 
 
                  Three Months Ended      Nine Months Ended 
                     September 30,          September 30, 
                 --------------------  ----------------------- 
                   2026       2025       2026         2025 
                 ---------  ---------  ---------  ------------ 
Net loss 
 attributable 
 to Maravai 
 LifeSciences 
 Holdings, 
 Inc.            $(13,839)  $(25,556)  $(29,988)  $ (95,092) 
Net loss impact 
 from pro forma 
 conversion of 
 Class B shares 
 to Class A 
 common shares    (10,161)   (19,501)   (22,020)    (72,655) 
Adjustment to 
 the provision 
 for income tax 
 (10)               2,486      4,644      5,388      17,304 
                  -------    -------    -------    -------- 
Tax-effected 
 net loss         (21,514)   (40,413)   (46,620)   (150,443) 
Acquisition 
 integration 
 costs (1)            312        847        761       2,445 
Stock-based 
 compensation 
 (2)               10,115      9,056     27,063      26,248 
Merger and 
 acquisition 
 related 
 expenses (3)          --         --         --       1,270 
Loss on 
extinguishment 
of debt                --         --      3,413          -- 
Acquisition 
 related tax 
 adjustment 
 (4)                   --         --         --       4,082 
Executive 
 leadership 
 transition 
 costs (5)             --         17         --       2,024 
Goodwill 
 impairment 
 (6)                   --         --         --      42,884 
Property and 
 equipment 
 impairment 
 (7)                   --          7         --       1,059 
Restructuring 
 costs (8)          2,903      6,932      5,980       6,932 
Other (9)             933        292      3,697       2,846 
Tax impact of 
 adjustments 
 (11)                (160)     1,932     (2,973)     (1,950) 
                  -------    -------    -------    -------- 
Adjusted net 
 loss 
 (non-GAAP)      $ (7,411)  $(21,330)  $ (8,679)  $ (62,603) 
                  =======    =======    =======    ======== 
 
Diluted 
 weighted 
 average shares 
 of Class A 
 common stock 
 outstanding 
 (non-GAAP)       275,974    257,019    269,571     255,943 
 
Adjusted loss 
 (non-GAAP)      $ (7,411)  $(21,330)  $ (8,679)  $ (62,603) 
Adjusted fully 
 diluted loss 
 per share 
 (non-GAAP)      $  (0.03)  $  (0.08)  $  (0.03)  $   (0.24) 
 
 
____________________ 
Explanatory Notes to Reconciliations 
(1)     Refers to incremental costs incurred to execute and integrate 
        completed acquisitions, including retention payments related to 
        integration that were negotiated specifically at the time of the 
        Company's acquisition of Alphazyme, which was completed in January 
        2023. These retention payments were from the Company's agreement 
        executed in connection with its acquisition of Alphazyme and provided 
        incremental financial incentives, over and above recurring 
        compensation, to ensure the employees of Alphazyme remained present 
        and participated in integration of the acquired business during the 
        integration and knowledge transfer period. The Company agreed to pay 
        certain employees of Alphazyme retention payments totaling $9.3 
        million as of various dates but primarily through December 31, 2025, 
        as long as these individuals continued to be employed by the Company. 
        The Company recognized compensation expense related to these payments 
        in the post-acquisition period ratably over the service period, with 
        certain costs capitalized into inventory. Retention payment expenses 
        were $0.7 million and $2.2 million for the three and nine months ended 
        September 30, 2025, respectively. Retention expenses for Alphazyme 
        concluded in the fourth quarter of 2025, and following the payments in 
        the fourth quarter of 2025, there were no further retention expenses 
        payable for Alphazyme. There are no further cash-based retention 
        payments planned as of September 30, 2026. The remaining expenses 
        incurred reflect the impact to cost of revenue for the retention 
        bonuses previously capitalized into inventory as the inventory is 
        sold. 
(2)     Refers to non-cash expense associated with stock-based compensation. 
(3)     Refers to diligence, legal, accounting, tax and consulting fees 
        incurred in connection with acquisitions that were pursued but not 
        consummated. 
(4)     Refers to non-cash expense associated with adjustments to the 
        indemnification asset recorded in connection with the acquisition of 
        MyChem. 
(5)     Refers to costs associated with the Executive Leadership Transition 
        that occurred in June 2025, including severance and legal costs. For 
        the nine months ended September 30, 2025, stock-based compensation 
        benefit of $(3.3) million primarily related to forfeited stock awards 
        in connection with the Executive Leadership Transition is included on 
        the stock-based compensation line item. For the three months ended 
        September 30, 2025, there was no such stock-based compensation benefit 
        amount. 
(6)     Refers to goodwill impairment recorded for our TriLink segment. 
(7)     Refers to non-cash charges to write-down surplus laboratory equipment 
        to estimated fair value, less costs to sell. 
(8)     Refers to restructuring costs associated with the 2025 Corporate 
        Realignment Plan. For the nine months ended September 30, 2026, 
        stock-based compensation benefit of ($0.2 million) related to 
        forfeited stock awards is included in the stock-based compensation 
        line item. For the three months ended September 30, 2026 there was no 
        such stock-based compensation benefit amount. For the three and nine 
        months ended September 30, 2025, stock-based compensation expense of 
        $0.5 million related to forfeited stock awards in connection with the 
        2025 Corporate Realignment Plan is included in the stock-based 
        compensation line item. For the three and nine months ended September 
        30, 2026, there was a nominal amount of depreciation expense primarily 
        related to the 2025 Corporate Realignment Plan is included in the 
        depreciation line item. For the three and nine months ended September 
        30, 2025, there was no restructuring related depreciation expense. 
(9)     For the three and nine months ended September 30, 2026 and for the 
        three and nine months ended September 30, 2025, refers to severance 
        expense, inventory step-up charges in connection with the acquisition 
        of Alphazyme, non-recurring legal costs, change in the estimated fair 
        value of contingent consideration related to completed acquisitions, 
        and other non-recurring costs that are deemed to be outside of the 
        ordinary course of business. 
(10)    Represents additional corporate income taxes at an assumed effective 
        tax rate of approximately 24% applied to additional net loss 
        attributable to Maravai LifeSciences Holdings, Inc. from the assumed 
        proforma exchange of all outstanding shares of Class B common stock 
        for shares of Class A common stock. 
(11)    Represents income tax impact of non-GAAP adjustments at an assumed 
        effective tax rate of approximately 24% and the assumed proforma 
        exchange of all outstanding shares of Class B common stock for shares 
        of Class A common stock. 
 

Non-GAAP Financial Information

This press release contains financial measures that have not been calculated in accordance with accounting principles generally accepted in the U.S. (GAAP). These non-GAAP measures include: Adjusted EBITDA and Adjusted fully diluted Earnings Per Share (EPS).

Maravai defines Adjusted EBITDA as net income (loss) before interest, taxes, depreciation and amortization, certain non-cash items and other adjustments that we do not consider representative of our ongoing operating performance from period to period. Maravai defines Adjusted Net Income (Loss) as tax-effected earnings before the adjustments described above, and the tax effects of those adjustments. Maravai defines Adjusted fully diluted EPS as Adjusted Net Income (Loss) divided by the diluted weighted average number of shares of Class A common stock outstanding for the applicable period, which assumes the proforma exchange of all outstanding units of Maravai Topco Holdings, LLC (paired with shares of Class B common stock) for shares of Class A common stock.

These non-GAAP measures are supplemental measures of operating performance that are not prepared in accordance with GAAP and do not represent, and should not be considered as, an alternative to net loss, as determined in accordance with GAAP.

Management uses these non-GAAP measures to understand and evaluate Maravai's core operating performance and trends, and to develop short-term and long-term operating plans. Management believes the measures facilitate comparison of Maravai's operating performance on a consistent basis between periods and, when viewed in combination with its results prepared in accordance with GAAP, help provide a broader picture of factors and trends affecting Maravai's results of operations.

These non-GAAP financial measures have limitations as an analytical tool, and you should not consider them in isolation, or as a substitute for analysis of Maravai's results as reported under GAAP. Because of these limitations, they should not be considered as a replacement for net loss, as determined by GAAP, or as a measure of Maravai's profitability. Management compensates for these limitations by relying primarily on Maravai's GAAP results and using non-GAAP measures only for supplemental purposes. The non-GAAP financial measures should be considered supplemental to, and not a substitute for, financial information prepared in accordance with GAAP.

About Maravai

Maravai is a leading life sciences company providing critical products to enable the development of drug therapies, diagnostics and novel vaccines and to support research on human diseases. Maravai's companies are leaders in providing products and services in the fields of nucleic acid synthesis and biologics safety testing to many of the world's leading biopharmaceutical, vaccine, diagnostics, and cell and gene therapy companies.

For more information about Maravai LifeSciences, visit www.maravai.com.

Forward-looking Statements

This press release contains, and Maravai's officers and representatives may from time to time make, "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Investors are cautioned that statements in this press release that are not strictly historical statements constitute forward-looking statements, including, without limitation, statements regarding Maravai's expected revenue and EBITDA performance for the full year 2026, including its expectations for the fourth quarter of 2026; the expectation that customer programs at the Discovery stage will advance into clinical and commercial development and create GMP opportunities for TriLink; Maravai's ability to execute on its strategy to drive sustained, profitable growth; and Maravai's ability to create long-term value for its shareholders, constitute forward-looking statements and are identified by words like "anticipate," "believe," "continue," "could," "estimate," "expect," "guidance," "intend," "may," "plan," "project," "see," "seek," "should," "target," "will," or "would" and similar expressions.

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on management's current beliefs, expectations and assumptions regarding the future of Maravai's business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of management's control. Maravai's actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause Maravai's actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following:

   --  The level of Maravai's customers' spending on and demand for TriLink 
      and Cygnus products and services. 
 
   --  Maravai's operating results are prone to significant fluctuation, which 
      may make Maravai's future operating results difficult to predict and 
      could cause Maravai's actual operating results to fall below expectations 
      or any guidance Maravai may provide. 
 
   --  Uncertainty regarding the extent and duration of Maravai's revenue 
      associated with high-volume sales of CleanCap(R) for commercial phase 
      vaccine programs and the dependency of such revenue, in important 
      respects, on factors outside our control. 
 
   --  Shifts in the trade, economic and other policies and priorities of the 
      U.S. federal government, on Maravai and Maravai's customers' current and 
      future business operations. 
 
   --  Unintended consequences from our recent organizational changes and 
      workforce reduction. 
 
   --  Use of Maravai's products by customers in the production of vaccines 
      and therapies, some of which represent relatively new and 
      still-developing modes of treatment, and the impact of unforeseen adverse 
      events, negative clinical outcomes, development of alternative therapies, 
      or increased regulatory scrutiny of these modes of treatment and their 
      financial cost on Maravai's customers' use of its products and services. 
 
 
   --  Competition with life science, pharmaceutical and biotechnology 
      companies who are substantially larger than Maravai and potentially 
      capable of developing new approaches that could make Maravai's products, 
      services and technology obsolete. 
 
   --  The potential failure of Maravai's products and services to perform as 
      expected and the reliability of the technology on which Maravai's 
      products and services are based. 
 
   --  Maravai's use of Artificial Intelligence technologies, including 
      Machine Learning, and business, compliance and reputational challenges 
      that may result from such use. 
 
   --  The risk that Maravai's products do not comply with required quality 
      standards. 
 
   --  Market acceptance of Maravai's life science reagents. 
 
   --  Maravai's ability to efficiently manage its strategic acquisitions and 
      organic growth opportunities. 
 
   --  Natural disasters, geopolitical instability (including ongoing military 
      conflicts) and other catastrophic events. 
 
   --  Risks related to Maravai's acquisitions, including whether Maravai 
      achieves the anticipated benefits of acquisitions of businesses or 
      technologies. 
 
   --  Product liability lawsuits. 
 
   --  Maravai's dependency on a limited number of customers for a high 
      percentage of its revenue and Maravai's ability to maintain its current 
      relationships with such customers. 
 
   --  Maravai's reliance on a limited number of suppliers or, in some cases, 
      sole suppliers, for some of Maravai's raw materials and the risk that 
      Maravai may not be able to find replacements or immediately transition to 
      alternative suppliers. 
 
   --  The risk that Maravai's products become subject to more onerous 
      regulation by the U.S. Food and Drug Administration or other regulatory 
      agencies in the future. 
 
   --  Maravai's ability to obtain, maintain and enforce sufficient 
      intellectual property protection for Maravai's current or future 
      products. 
 
   --  The risk that a future cyber-attack or security breach cannot be 
      prevented. 
 
   --  Maravai's ability to protect the confidentiality of Maravai's 
      proprietary information. 
 
   --  The risk that one of Maravai's products may be alleged (or found) to 
      infringe on the intellectual property rights of third parties. 
 
   --  Compliance with Maravai's obligations under intellectual property 
      license agreements. 
 
   --  Maravai's or Maravai's licensors' failure to maintain the patents or 
      patent applications in-licensed from a third party. 
 
   --  Maravai's ability to adequately protect Maravai's intellectual property 
      and proprietary rights throughout the world. 
 
   --  Maravai's existing level of indebtedness and Maravai's ability to raise 
      additional capital on favorable terms. 
 
   --  Maravai's ability to generate sufficient cash flow to service all of 
      Maravai's indebtedness. 
 
   --  Maravai's potential failure to meet Maravai's debt service 
      obligations. 
 
   --  Restrictions on Maravai's current and future operations under the terms 
      applicable to Maravai's credit agreement. 
 
   --  Maravai's dependence, by virtue of Maravai's principal asset being its 
      interest in Maravai Topco Holdings, LLC ("Topco LLC"), on distributions 
      from Topco LLC to pay Maravai's taxes and expenses, including payments 
      under a tax receivable agreement with the former owners of Topco LLC (the 
      "Tax Receivable Agreement" or "TRA") together with various limitations 
      and restrictions that impact Topco LLC's ability to make such 
      distributions. 
 
   --  The risk that conflicts of interest could arise between Maravai's 
      shareholders and Maravai Life Sciences Holdings, LLC ("MLSH 1"), the only 
      other member of Topco LLC, and impede business decisions that could 
      benefit Maravai's shareholders. 
 
   --  The substantial future cash payments Maravai may be required to make 
      under the Tax Receivable Agreement to MLSH 1 and Maravai Life Sciences 
      Holdings 2, LLC ("MLSH 2"), an entity through which certain of Maravai's 
      former owners hold their interests in the Company and the negative effect 
      of such payments. 
 
   --  The fact that Maravai's organizational structure, including the TRA, 
      confers certain benefits upon MLSH 1 and MLSH 2 that will not benefit 
      Maravai's other common shareholders to the same extent as they will 
      benefit MLSH 1 and MLSH 2. 
 
   --  Maravai's ability to realize all or a portion of the tax benefits that 
      are expected to result from the tax attributes covered by the Tax 
      Receivable Agreement. 
 
   --  The possibility that Maravai will receive distributions from Topco LLC 
      significantly in excess of Maravai's tax liabilities and obligations to 
      make payments under the Tax Receivable Agreement. 
 
   --  Factors that could lead to future impairment of Maravai's goodwill and 
      other amortizable intangible assets. 
 
   --  Unanticipated changes in effective tax rates or adverse outcomes 
      resulting from examination of Maravai's income or other tax returns. 
 
   --  Maravai's ability to design and maintain effective internal control 
      over financial reporting in the future. 
 
   --  The fact that investment entities affiliated with GTCR, LLC currently 
      control a majority of the voting power of Maravai's outstanding common 
      stock, and it may have interests that conflict with Maravai's or yours in 
      the future. 
 
   --  Risks related to Maravai's "controlled company" status within the 
      meaning of the corporate governance standards of NASDAQ. 
 
   --  The potential anti-takeover effects of certain provisions in Maravai's 
      corporate organizational documents. 
 
   --  Potential sales of a significant portion of Maravai's outstanding 
      shares of Class A common stock. 
 
   --  Potential preferred stock issuances and the anti-takeover impacts of 
      any such issuances. 
 
   --  Such other factors as discussed throughout the sections entitled "Risk 
      Factors" and "Management's Discussion and Analysis of Financial Condition 
      and Results of Operations" in Maravai's most recent Annual Report on Form 
      10-K, Quarterly Reports on Form 10-Q, as well as other documents Maravai 
      files with the Securities and Exchange Commission. 

Any forward-looking statements made in this release are based only on information currently available to management and speak only as of the date on which it is made. Maravai undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20261104432622/en/

 
    CONTACT:    Deb Hart 

Maravai LifeSciences

+ 1 858-988-5917

ir@maravai.com

 
 

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment